Alert: New Earnings Report (11/7/19)-Lexicon Pharmaceuticals Inc (NASDAQ: LXRX).


Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) has reported E.P.S. of $2.13 for its third fiscal quarter (ending September 30) versus $-0.26 for the same period a year ago. Relative to the consensus estimate of $0.73, this was a premium of $1.40. E.P.S. were $1.55 for the latest four quarters through September 30 versus $-1.25 for the same period a year ago.


Recent Price Action

Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) stock closed at $3.88 on 11/7/19 after a modest gain of 0.8%. NORMAL trading volume accompanied the advance. The stock has been extremely weak relative to the market over the last nine months but has risen 1.0% during the last week.

Current PriceTarget Research Rating

LXRX is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.

LXRX is currently unrated.

Rating Review

The stock is currently unrated.

About John Lafferty 79039 Articles
During his career, John has developed valuation and stock rating methodologies, managed institutional portfolios and mutual funds, and provided equity research to institutional investors on thousands of companies. He has been Director of Research at PTR since its inception in 2004.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.